Skip to main content
OpenTrials
Completed

NCT Number: NCT04875455

Premium Trifocal IOL Comparative Analysis

Short and long-term analysis of the refraction correction and optical image quality of modern premium intraocular lenses (IOLs) with the establishment of a database for quality assurance and optimization the computation constants of the lens power.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Augenklinik Ahaus, Ahaus, Germany

Loading trial locations.

About this study

Since the investigational lens, like conventional IOLs, is a posterior chamber lens which is widely implanted following cataract extraction, phacoemulsification is adopted. To assess the binocular vision, the investigational lens will be mono- or bilaterally implanted.

Clinically retro- and prospective, non-randomized, uncontrolled, open study at several centers: University Eye Clinic Heidelberg (leading center), Practice Center Ahaus in the Eye Clinic Ahaus, Breyer, Kaymak & Klabe Eye Surgery in Düsseldorf, nordBLICK Eye Center Kiel.

Main objectives:

  • Functional results (refraction and visual acuity results) Secondary goals:
  • Deviation target vs. achieved postoperative refraction (for constant optimization of the IOL calculation)
  • Subjective patient satisfaction
  • Visual quality (e.g. scattered light, contrast vision, spherical aberrations)
  • Stability of the results achieved postoperatively

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Bilateral implantation of one of the following IOL models
  • Alcon PanOptix (TFNT00)
  • PhysIOL FineVision (POD F)
  • PhysIOL FineVision (POD F GF)
  • Uneventful cataract surgery with first clinical outcomes in the expected range
  • Patient included in Premium IOL study protocol by signed informed consent

Exclusion criteria

  • Age of patient <45 years
  • Irregular astigmatism
  • Postoperative manifested astigmatism of >1.0 D
  • Difficulty for cooperation (distance from their home, general health condition)
  • Clinically significant glaucoma
  • Clinically significant macular degeneration, clinically significant macular edema or proliferative diabetic retinopathy
  • Patients with keratoconus or keratectasia
  • Any ocular comorbidity having a significant effect on the postoperative clinical outcomes
  • History of ocular trauma or prior ocular surgery including refractive procedures
  • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)
  • Pupil abnormalitis (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions)
  • AMD
  • Intraoperative complications like capsular rupture etc.
  • Patients who do not give informed consent

Treatment and study plan

POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation

Device

In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.

Primary outcomes

  1. Monocular Best corrected distance visual acuity (5 m)

    Time frame: Postoperative Day 75-105 (3 months)

    CDVA measured with ETDRS charts placed in 5m distance with best aided corrective glasses according to ISO 11979-7:2014.

Sponsors and collaborators

Lead sponsor

Beaver-Visitec International, Inc.

Industry

Registry information

Official study title

Development of a Database (Register) for Quality Assurance and Optimization of the Postoperative Results of Premium Intraocular Lenses

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
May 6, 2021
Registry last updated
Jan 11, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.